ADMA Biologics Under Investigation for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy ADMA?
Source: Newsfilter
- Channel Stuffing Allegations: A report by Culper Research revealed that ADMA Biologics allegedly induced a distributor to stock excess ASCENIV in 2025 by offering rebates and extended payment terms, resulting in a reported growth of 20% that masked a real decline of 3%.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by ADMA Biologics, which could lead to severe legal repercussions, negatively impacting the company's reputation and shareholder confidence.
- Investor Losses: The report indicates that investors who suffered losses exceeding $50,000 in ADMA Biologics securities may be eligible to participate in litigation, which could adversely affect the company's future financing capabilities and market performance.
- Firm Background: Lowey Dannenberg is a national law firm with significant experience in securities and antitrust law, having recovered billions for investors, highlighting its strength and influence in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Shares Plunge 16% Following Short Seller Report
- Stock Price Plunge: ADMA Biologics shares fell over 16% on March 24, 2026, following a report from short seller Culper Research that revealed issues of channel stuffing and undisclosed related party distributors, severely undermining investor confidence.
- Investigation Launched: Hagens Berman has initiated an investigation into ADMA to determine potential violations of federal securities laws, particularly regarding the compliance of its financial reporting, which could impact the company's future legal liabilities and financial stability.
- Accounts Receivable Surge: The report highlighted a dramatic increase in ADMA's days sales outstanding (DSO) to 113 days as of December 31, 2025, up 70 days from the previous year, indicating risks of artificially inflating revenue through rebates and extended payment terms.
- Market Reaction: Following the report, ADMA's stock price swiftly declined, and analysts downgraded their ratings from overweight to neutral, reflecting serious market concerns about the company's financial health, potentially leading to further investor sell-offs.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm announces an investigation into ADMA Biologics for potentially issuing materially misleading business information, indicating that shareholders may be entitled to compensation if they purchased the company's securities.
- Stock Price Impact: On March 24, 2026, ADMA Biologics shares plummeted by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no out-of-pocket fees required from investors, highlighting the firm's commitment to protecting shareholder rights.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and experience in handling such cases.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Launched: The Law Offices of Howard G. Smith are investigating ADMA Biologics for potential violations of federal securities laws, aiming to assist investors in recovering losses, highlighting serious concerns regarding the company's compliance.
- Allegations Reported: On March 24, 2026, Culper Research published a report accusing ADMA of 'channel stuffing' and undisclosed related party distributors, with actual growth in 2025 reported at -3% compared to +20%, revealing significant risks of financial misrepresentation.
- Executive Testimonies: The report noted that two high-level employees from one of ADMA's largest distributors independently confirmed that starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms, leading to inflated revenue reporting that harmed investor interests.
- Stock Price Plummet: Following the news, ADMA's stock price fell by $3.96, or 29.1%, over two consecutive trading days, closing at $9.63 per share, directly impacting investor asset values and reflecting a crisis of trust in the company's financial transparency.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Reasons: Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws, as allegations arise that the company falsely reported a 20% revenue growth in 2025 through a channel stuffing scheme to mask declining demand.
- False Revenue Claims: A report by Culper Research revealed that ADMA Biologics allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to report growth that was not actually present, with a potential revenue decline of 3% instead of the reported growth.
- Stock Price Plummet: This news resulted in a 29% drop in ADMA Biologics' stock price over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating significant market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to contact BFA for potential legal options, as the firm offers contingency fee representation, ensuring shareholders are not responsible for litigation costs, which underscores their commitment to protecting investor rights.
See More
ADMA Biologics Under Investigation for Securities Claims
- Investigation Launched: Rosen Law Firm has initiated an investigation into ADMA Biologics for potential securities claims due to allegations of issuing materially misleading business information, allowing affected shareholders to seek compensation without upfront costs.
- Stock Price Impact: On March 24, 2026, ADMA Biologics' shares plummeted by 16.6% following a report from short seller Culper Research, which accused the company of channel stuffing to inflate revenue growth, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit aimed at recovering investor losses, with the contingency fee arrangement likely to encourage more affected shareholders to participate without any out-of-pocket expenses.
- Law Firm's Credentials: Renowned for its success in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases effectively.
See More
ADMA Biologics Under Investigation for Securities Violations
- Channel Stuffing Allegations: A report by Culper Research reveals that ADMA Biologics induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms in 2025, which allegedly allowed the company to report a false growth of 20% instead of a projected revenue decline of 3%.
- False Growth Exposure: The report indicates that the growth reported by ADMA Biologics was achieved through improper means, potentially damaging investor confidence as the actual performance was negative, raising concerns about the company's financial integrity.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether ADMA Biologics and its executives provided accurate and complete information to investors, which could lead to legal liabilities and negatively impact the company's reputation and stock price.
- Investor Loss Warning: Investors who suffered losses exceeding $50,000 in ADMA Biologics securities are encouraged to participate in the investigation, indicating that potential collective lawsuits could exert further financial pressure on the company.
See More
ADMA Biologics Shares Plunge 16% Following Short Seller Report
- Stock Price Plunge: ADMA Biologics shares fell over 16% on March 24, 2026, following a report from short seller Culper Research that revealed issues of channel stuffing and undisclosed related party distributors, severely undermining investor confidence.
- Investigation Launched: Hagens Berman has initiated an investigation into ADMA to determine potential violations of federal securities laws, particularly regarding the compliance of its financial reporting, which could impact the company's future legal liabilities and financial stability.
- Accounts Receivable Surge: The report highlighted a dramatic increase in ADMA's days sales outstanding (DSO) to 113 days as of December 31, 2025, up 70 days from the previous year, indicating risks of artificially inflating revenue through rebates and extended payment terms.
- Market Reaction: Following the report, ADMA's stock price swiftly declined, and analysts downgraded their ratings from overweight to neutral, reflecting serious market concerns about the company's financial health, potentially leading to further investor sell-offs.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm announces an investigation into ADMA Biologics for potentially issuing materially misleading business information, indicating that shareholders may be entitled to compensation if they purchased the company's securities.
- Stock Price Impact: On March 24, 2026, ADMA Biologics shares plummeted by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no out-of-pocket fees required from investors, highlighting the firm's commitment to protecting shareholder rights.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and experience in handling such cases.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Launched: The Law Offices of Howard G. Smith are investigating ADMA Biologics for potential violations of federal securities laws, aiming to assist investors in recovering losses, highlighting serious concerns regarding the company's compliance.
- Allegations Reported: On March 24, 2026, Culper Research published a report accusing ADMA of 'channel stuffing' and undisclosed related party distributors, with actual growth in 2025 reported at -3% compared to +20%, revealing significant risks of financial misrepresentation.
- Executive Testimonies: The report noted that two high-level employees from one of ADMA's largest distributors independently confirmed that starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms, leading to inflated revenue reporting that harmed investor interests.
- Stock Price Plummet: Following the news, ADMA's stock price fell by $3.96, or 29.1%, over two consecutive trading days, closing at $9.63 per share, directly impacting investor asset values and reflecting a crisis of trust in the company's financial transparency.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Reasons: Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws, as allegations arise that the company falsely reported a 20% revenue growth in 2025 through a channel stuffing scheme to mask declining demand.
- False Revenue Claims: A report by Culper Research revealed that ADMA Biologics allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to report growth that was not actually present, with a potential revenue decline of 3% instead of the reported growth.
- Stock Price Plummet: This news resulted in a 29% drop in ADMA Biologics' stock price over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating significant market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to contact BFA for potential legal options, as the firm offers contingency fee representation, ensuring shareholders are not responsible for litigation costs, which underscores their commitment to protecting investor rights.
See More
ADMA Biologics Under Investigation for Securities Claims
- Investigation Launched: Rosen Law Firm has initiated an investigation into ADMA Biologics for potential securities claims due to allegations of issuing materially misleading business information, allowing affected shareholders to seek compensation without upfront costs.
- Stock Price Impact: On March 24, 2026, ADMA Biologics' shares plummeted by 16.6% following a report from short seller Culper Research, which accused the company of channel stuffing to inflate revenue growth, significantly undermining investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit aimed at recovering investor losses, with the contingency fee arrangement likely to encourage more affected shareholders to participate without any out-of-pocket expenses.
- Law Firm's Credentials: Renowned for its success in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases effectively.
See More
ADMA Biologics Under Investigation for Securities Violations
- Channel Stuffing Allegations: A report by Culper Research reveals that ADMA Biologics induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms in 2025, which allegedly allowed the company to report a false growth of 20% instead of a projected revenue decline of 3%.
- False Growth Exposure: The report indicates that the growth reported by ADMA Biologics was achieved through improper means, potentially damaging investor confidence as the actual performance was negative, raising concerns about the company's financial integrity.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether ADMA Biologics and its executives provided accurate and complete information to investors, which could lead to legal liabilities and negatively impact the company's reputation and stock price.
- Investor Loss Warning: Investors who suffered losses exceeding $50,000 in ADMA Biologics securities are encouraged to participate in the investigation, indicating that potential collective lawsuits could exert further financial pressure on the company.
See More
